This trial is active, not recruiting.

Condition huntington disease
Sponsor Huntington Study Group
Collaborator National Human Genome Research Institute (NHGRI)
Start date July 1999
End date July 2010
Trial size 1001 participants
Trial identifier NCT00052143, R01HG02449


The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Eligibility Criteria

Male or female participants from 26 years up to 55 years old.

Inclusion: - Men and women between 26-55 years of age; - Who are at risk for HD by virtue of having (or had) a parent or sibling with the illness; - Who have never been tested for the HD gene, and who do not desire to be tested for the HD gene during the duration of the study; - Agree to blinded (sample will be coded) genetic testing of the HD gene; and - Who have never been diagnosed with HD. Exclusion: Individuals Who: - have been diagnosed with HD; - are taking antipsychotic medications; - use antiemetic (anti-nausea) medications with on a regular basis (greater than 3 times per month); or - exhibit clinical signs/symptoms of psychosis at the screening visit

Additional Information

Official title Prospective Huntington At Risk Observational Study (PHAROS)
Principal investigator Ira Shoulson, M.D.
Description Huntington's disease (HD) is a genetic disease characterized by changes in movement and behavior. To date, little research has been done on individuals who are at risk for developing the disease. PHAROS is an observational study designed to monitor people who are at risk for developing HD, and to survey their attitudes and beliefs about their "at-risk" status. Investigators hope this study will help answer some important questions about HD, such as: 1.) What are the earliest signs of HD and when do they start? 2.) How accurate are the measures that physicians use in detecting the onset of HD? 3.) What factors influence the age at which a person carrying the HD gene develops the illness? and 4.) In a group of people at risk for HD, how many will develop signs of the illness over a minimum three-year period of observation? Participants in the study will be evaluated every 9 months (for 5 years) using the Unified Huntington's Disease Rating Scale (UHDRS)--a clinical tool which looks at movement, psychological and behavioral function. The participants will also be asked to complete surveys about their mood, life events, and attitudes or beliefs about being at risk for HD. A blood sample, taken at the beginning of the study, will be confidentially tested to determine if the participant has the abnormal gene for HD. Neither the participant nor any of the PHAROS physicians or coordinators will learn the results of individual gene tests. The scientists hope that this study will provide essential information for future trials of experimental drugs for HD.
Trial information was received from ClinicalTrials.gov and was last updated in April 2009.
Information provided to ClinicalTrials.gov by Huntington Study Group.